MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    A Physiotherapy Exercise Program for Parkinson’s Disease Patients with Impaired Gait and Postural Control

    J. Yeung, A. Lau, E. Chan, J. Chung, L. Chan (Hong Kong)

    Objective: To improve the gait stability of Parkinson's disease(PD) patients by physiotherapy and gait skill training. Background: Current pharmacological therapy for PD is largely based…
  • 2018 International Congress

    Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease

    J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)

    Objective: To emulate physiological dopamine receptor activation, in order to restore temporal patterns of dopamine-like signalling and normalise function in the striatum in Parkinson's disease.…
  • 2018 International Congress

    TreCap: Quantify and assess tremor in real-time with a new wearable device

    R. Bremm, J. Goncalves, K. Koch, F. Hertel (Belvaux, Luxembourg)

    Objective: To develop a wearable device with novel software features for real-time analysis and assessment of tremor in the clinical environment. Background: Visual examination of…
  • 2018 International Congress

    Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

    S. Iqbal (Chennai, India)

    Objective: To validate effect of Indolocarbazole derivatives on Cyclin dependent kinase for treating Parkinson's (Preliminary work in context of CDK5 assay and Simulations have been…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Does the effect of continuous levodopa infusion treatment for Parkinson’s disease regress as the day progresses?

    I. Thomas, M. Memedi, D. Nyholm, J. Westin (Borlange, Sweden)

    Objective: The goal of this project is to examine if there is evidence to suggest that there is a difference in response to levodopa during…
  • 2018 International Congress

    Efficacy and safety of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: A systematic review of randomized controlled trials

    S. Hussain, A. Najmi (New Delhi, India)

    Objective: To assess the efficacy and safety of safinamide as an add-on therapy to levodopa in Parkinson patients. Background: Long-term use of levodopa is associated…
  • 2018 International Congress

    Efficacy of ND0612 for nocturnal problems and early morning OFF

    F. Stocchi, W. Poewe, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: ND012 is a drug-device combination delivering liquid L-dopa/carbidopa (LD/CD) via continuous SC infusion. This secondary analysis evaluated the efficacy of 2 dosing regimens (R1:…
  • 2018 International Congress

    Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

    R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

    Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone…
  • 2018 International Congress

    Gait speed after applying anodal-transcranial Direct Current Stimulation in people with Parkinson’s disease? Preliminary results

    V. Alizad, M. Meinzer, L. Frossard, R. Polman, S. Smith, G. Kerr (Brisbane, Australia)

    Objective: The objective of this study was to explore the effects of anodal-tDCS with two different montages on gait speed in people with PD. Background:…
  • « Previous Page
  • 1
  • …
  • 1216
  • 1217
  • 1218
  • 1219
  • 1220
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley